Survival of Patients with Isolated Peritoneal Carcinomatosis from Colorectal cancer: 23 Years Experience Using Conventional Treatment

U Shariff, L Taylor, A Coupland, J Glaholm, H Youssef

Midlands Peritoneal Malignancy Unit
Good Hope Hospital
Heart of England NHS Foundation Trust
Sutton Coldfield
Peritoneal Metastases from colorectal cancer (PM-CRC)

- Peritoneal metastasis, in the absence of distant metastases is uncommon, occurs in 3-10% cases

- PM-CRC is associated with poor prognosis

- Survival rates are poor with conventional treatments, with studies traditionally showing median survival of 6-12 months
Background

- Cytoreductive Surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) is a radical surgical strategy to tackle PM-CRC

- Technique practiced in our unit for last 2.5 years

- Prior to introduction of CRS/HIPEC, conventional treatments used:
  - Resection of primary + chemotherapy
  - Chemotherapy only
  - Surgery only
Aim

- To investigate the survival of patients with isolated PM-CRC using conventional treatments prior to introduction of CRS and HIPEC in our unit
Methods

Data on all patients with PM-CRC (synchronous or metachronous) retrospectively collected (1989-2012)

Data collected on:
- Demographics
- Tumour distribution
- Treatment modalities
- Survival

Patients with distant metastases were excluded
Results

- Data available on 36 patients (90%)

- Median age: 65 years (range: 33-80)

- Male (56%): Female (44%)
Tumour site distribution

- Rectum: 22%
- Ascending Colon: 20%
- Sigmoid Colon: 11%
- Unknown: 14%
- Caecum: 14%
- Appendix: 8%
- Descending Colon: 8%
- Transverse Colon: 3%
Treatment modality

- Surgery + chemotherapy: 24
- Chemotherapy only: 9
- Surgery only: 3
Survival: All groups

<table>
<thead>
<tr>
<th>Interval from time from diagnosis to death (months)</th>
<th>Cumulative Survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>1.0</td>
</tr>
<tr>
<td>10</td>
<td>0.9</td>
</tr>
<tr>
<td>20</td>
<td>0.8</td>
</tr>
<tr>
<td>30</td>
<td>0.7</td>
</tr>
<tr>
<td>40</td>
<td>0.6</td>
</tr>
<tr>
<td>50</td>
<td>0.5</td>
</tr>
<tr>
<td>60</td>
<td>0.4</td>
</tr>
<tr>
<td>70</td>
<td>0.3</td>
</tr>
<tr>
<td>80</td>
<td>0.2</td>
</tr>
<tr>
<td>90</td>
<td>0.1</td>
</tr>
<tr>
<td>100</td>
<td>0.0</td>
</tr>
</tbody>
</table>

1 year | 2 year | 3 year | 5 year |
66.7%   | 37%    | 18.5%  | 3.7%   |

Overall median survival: 19.5 months (range 0–79)
Survival: treatment groups

**Graph: Cumulative Survival by Treatment**

- **Treatment**:
  - Chemotherapy only
  - Surgery only
  - Surgery + chemotherapy

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surgery + chemotherapy:</td>
<td>23 months</td>
</tr>
<tr>
<td>Chemotherapy only:</td>
<td>6 months</td>
</tr>
<tr>
<td>Surgery only:</td>
<td>7.5 months</td>
</tr>
</tbody>
</table>
Conclusions

- This study confirms poor survival from PM-CRC from conventional treatments with only 3.7% patients surviving 5 years.

- Patients who underwent primary resection and chemotherapy have better survival than other groups.

- Data provides a valuable baseline for PM-CRC patients prior to introduction of CRS/HIPEC.